摘要
Blocking the PI3K/AKT/mTOR pathway has been widely recognized as an attractive cancer therapeutic strategy because of its crucial role in cell growth and survival. In this study, a novel series of 2-arylurea-1,3,5-triazine derivatives had been synthesized and evaluated as highly potent PI3K and mTOR inhibitors. The new com-pounds exhibited cytotoxic activities against MCF-7, Hela and A549 cancer cell lines (IC50 = 0.03-36.54 mu M). The most promising compound XIN-9 exhibited potent inhibition against PI3K and mTOR kinase (IC50 = 23.8 and 10.9 nM). Mechanistic study using real-time PCR revealed the ability of XIN-9 to inhibit PI3K and mTOR. In addition, compound XIN-9 arrested the cell cycle of MCF-7 cells at the G0/G1 phase. XIN-9 also caused a sig-nificant dose-dependent increase of early and late apoptotic events. Molecular docking analysis revealed a high binding affinity for XIN-9 toward PI3K and mTOR. Following in vitro studies, XIN-9 was further evaluated in MCF-7 xenograft models to show significant in vivo anticancer efficacies with tumor growth inhibitions of 41.67% (po, 75 mg/kg). Overall, this work indicated that compound XIN-9 represents a potential anticancer targeting PI3K/AKT/mTOR pathway.
学科与关键词
- Design, synthesis and pharmacological evaluation of 2-arylurea-1,3,5-triazine derivative (XIN-9): A novel potent dual PI3K/mTOR inhibitor for cancer therapy (vol 129, 106157, 2022 )Sun, Xin; Zhang, Binliang; Luo, Leixuan; Yang, Yang; He, Bin; Zhang, Qian; Wang, Linxiao; Xu, Shan*; Zheng, Pengwu*; Zhu, Wufu*Bioorganic Chemistry, 2023, 131: 106336.
- Design, synthesis and bioevaluation of novel substituted triazines as potential dual PI3K/mTOR inhibitorsWu, Ting-Ting; Guo, Qing-Qing; Chen, Zi-Li; Wang, Li-Li; Du, Yao; Chen, Rui; Mao, Yuan-Hu; Yang, Sheng-Gang; Huang, Jing; Wang, Jian-Ta; Wang, Ling; Tang, Lei*; Zhang, Ji-Quan*European Journal of Medicinal Chemistry, 2020, 204: 112637.被引 26
- Function-oriented synthesis of Imidazo[1,2-a]pyrazine and Imidazo[1,2-b] pyridazine derivatives as potent PI3K/mTOR dual inhibitorsLi, Chuchu; Han, Yuqiao; Wang, Zhengyang; Yu, Yanan; Wang, Chen; Ren, Ziwei; Guo, Yanzhi; Zhu, Tong; Li, XuWen*; Dong, Suzhen*; Ma, Mingliang*European Journal of Medicinal Chemistry, 2023, 247: 115030.被引 2
